Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TBPH
HOLDTheravance Biopharma, Inc. · Healthcare · United States · $874M · Avg Vol: $14M/d
COMPANY DESCRIPTION
Theravance Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's competitive moat is built on its proprietary expertise in multivalent drug design, which optimizes therapeutic index and safety profiles. It operates as a specialized biotechnology player targeting respiratory and gastrointestinal diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.3M | 57.4M | 64.4M | 107.5M | 27.9% | 109.8M | 84.1M | 97.4M | -4.8% |
| EPS | 11.85 | -1.00 | -1.15 | 2.10 | -43.8% | 2.23 | — | — | — |
| Shares | 65.2M | 48.1M | 49.5M | 51.1M | -21.7% | 51.8M | — | — | — |
| Debt | 52.2M | 49.2M | 49.8M | 42.7M | -6.5% | 40.5M | — | — | — |
| Equity | 441.8M | 213.0M | 175.5M | 296.7M | -12.4% | — | — | — | — |
| Op CF | -187.0M | -27.0M | -11.5M | 238.5M | — | 268.8M | — | — | — |
| Inv CF | 1.2B | -32.7M | 12.3M | -105.3M | — | — | — | — | — |
| Fin CF | -758.8M | -198.9M | -2.5M | -3.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TBPH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TBPH | Theravance Biopharma, Inc.(you) | $874M | 54 | HOLD |
| FTH | Faeth Therapeutics, Inc. | $729M | 47 | HOLD |
| RLMD | Relmada Therapeutics, Inc. | $544M | 51 | HOLD |
| MNPR | Monopar Therapeutics Inc. | $736M | 44 | HOLD |
| LBRX | LB Pharmaceuticals Inc | $1.0B | 43 | HOLD |
| CLYM | Climb Bio, Inc. | $735M | 40 | HOLD |
| FTRE | Fortrea Holdings Inc. | $1.8B | 58 | HOLD |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $638M | 67 | BUY |
| ANAB | AnaptysBio, Inc. | $1.6B | 47 | HOLD |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 38 | HOLD |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.5%